Yusuf Hannun to Antineoplastic Agents
This is a "connection" page, showing publications Yusuf Hannun has written about Antineoplastic Agents.
Connection Strength
2.489
-
Synthesis of erythro- B13 enantiomers and stereospecific action of full set of B13-isomers in MCF7 breast carcinoma cells: Cellular metabolism and effects on sphingolipids. Bioorg Med Chem. 2021 02 15; 32:116011.
Score: 0.424
-
Ceramide launches an acute anti-adhesion pro-migration cell signaling program in response to chemotherapy. FASEB J. 2020 06; 34(6):7610-7630.
Score: 0.403
-
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase. PLoS One. 2017; 12(6):e0177805.
Score: 0.331
-
Hydroxyurea sensitivity reveals a role for ISC1 in the regulation of G2/M. J Biol Chem. 2009 Mar 27; 284(13):8241-6.
Score: 0.185
-
Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
Score: 0.179
-
Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008 Jan 15; 16(2):1032-45.
Score: 0.168
-
Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat. 2001 Dec; 4(6):368-77.
Score: 0.113
-
Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta. 2014 Aug; 1841(8):1174-88.
Score: 0.065
-
High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol. 1993 Jan; 43(1):37-44.
Score: 0.061
-
Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochem Cell Biol. 2012 Apr; 90(2):209-23.
Score: 0.058
-
Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells. BMC Cancer. 2011 Nov 07; 11:477.
Score: 0.056
-
Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J Biol Chem. 2011 Jul 15; 286(28):24754-64.
Score: 0.054
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.049
-
Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem. 2009 Mar 01; 17(5):1840-8.
Score: 0.046
-
Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem. 2008 Jan 15; 16(2):1015-31.
Score: 0.042
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.041
-
Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem. 2006 Nov 01; 14(21):7083-104.
Score: 0.039
-
Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg. 2005 Jan; 132(1):55-62.
Score: 0.035
-
Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells. J Pharmacol Exp Ther. 2004 Jun; 309(3):1051-9.
Score: 0.033
-
Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res. 2004 Jan 15; 292(2):385-92.
Score: 0.033
-
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. Cancer Immunol Res. 2021 05; 9(5):568-582.
Score: 0.027
-
Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis. J Immunol. 2021 03 15; 206(6):1395-1404.
Score: 0.027
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.011
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.010